

Opioid Analgesic: Short-Acting

Mei	mber Information					
1.	Last Name: 2. First Name:					
3.	Trillium ID #:	4. Date of Birth:	2. First Name: 5. Gender:		·	
Pres	scriber Information					
	Prescriber Name:					
3.	Requestor Name (Nurse/Office St	taff):				
4.	Mailing Address: Phone #:		City:	State:	Zip:	
3.	Phone #:	Ext	Fax #:			
Dru	g Information					
1.	Drug Name:	2. Strength:	3. C	uantity Per 30 Days:		
	Length of Therapy (in Days): \Box up					
Clin	ical Information					
1.	Does the member have a diagnosis of malignant cancer or pain due to neoplasm? Yes* No *If yes, the member is exempt from the prior authorization requirement					
			nt			
2. 3.	Does the member have Sickle Ce Is this an initial authorization requ		Lauthorization Solo	et 'No' for a requither	ization	
J.	request.	est? Select Tes 101 all lillia	i autilorization. Sele	ct ind idi a readindi	ization	
	□ Yes □ No					
	a. If No, please attach documentation as to why the member needs continued opioid treatment and current					
1	plan of care.	ambination with ather can	ourrant aniaida laa	es than ar agual to (Oma of	
4.	Is the requested daily dose in combination with other concurrent opioids less than or equal to 90mg of morphine or an equivalent dose? \Box Yes \Box No					
	Answer questions a and b when the response to question 4 is ' No '.					
	a. Please supply the member's diagnosis and reason for exceeding dose per day limits. Please list:					
		provide the duration (days supply) the member will exceed the limit of 90mg of morphine or an				
	equivalent dose.					
_	Please list:	in adhanina ta tha N.O. Madi		4		
5.	Has the prescriber reviewed and i		cai Board statement	on the use of control	ilea	
6.	substances for the treatment of pain? Yes No Is the prescribing clinician adhering, as medically appropriate, to the guidelines which include: (a) complete					
0.	member evaluation, (b) establishment of a treatment plan (contract), (c) informed consent, (d) periodic review, and					
7	(e) consultation with specialists in various treatment modalities as appropriate? ☐ Yes ☐ No Has the prescribing physician checked the member's utilization of controlled substances on the NC Controlled					
١٠.	Substance Reporting System?		n or controlled subs	lances on the NC CO	i ili Olleti	
8.	Has the prescribing clinician revie		ing for Proporihing (Onicida for Chronia D	oin? 🗆 Voc	
Ο.	□ No	wed the current CDC Guide	ine for Frescribing C	opiolas for Chilothic P		
No	on-Preferred Products:					
9.		ented history within the past	vear of two preferred	d long-acting Opioid	Analgesics at	
•	Does the member have a documented history within the past year of two preferred long-acting Opioid Analgesics a dose equal to or equivalent to the non-preferred long-acting Opioid Analgesic being prescribed? Yes No					
	Please list:			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	55 <u> </u>	
10	. Does the member have a contrain	ndication or allergy to ingred	ents in the preferred	•	No	
	Please list:					
C:	anature of Draceriber		D-4	٥.		
31	gnature of Prescriber:	rescriber Signature Mandato	Dati	e		
	-	_	• •	المالية	ا محمد من	
	I certify that the information provi	ded is accurate and complet	e to the best of my l	knowieage, and i und	uerstand	

that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.